Grifols, S.A. announces that it has acquired 51% of the share capital of Araclon Biotech, S.L.

Araclon Biotech is a company whose corporate activity is the research and development of therapies and methods for the diagnosis of degenerative illnesses, presently concentrating on Alzheimer’s disease.

Presently, the main activity of Araclon is to validate and market a blood diagnostic kit of Alzheimer’s disease for detecting beta amyloid proteins 40 and 42 (patented) and the development of an efficient immunotherapy treatment of Alzheimer's disease.

Araclon Biotech was founded by Dr Manuel Sarasa, who is the company’s Scientific Director.

Dr Manuel Sarasa is a neurobiologist and embryologist. He is a Lecturer of Anatomy and Comparative Pathological Anatomy for the University of Zaragoza, and has more than 25 years of experience in basic investigation and more than 18 years of research on subjects related to Alzheimer’s disease.

With this acquisition, Grifols reinforces its commitment to the research and development of therapies to fight Alzheimer's disease.